A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (tnbc) – nci

HIGHLIGHTS

• who: Foluso O. Ademuyiwa from the The study was approved by the National Cancer Institute (NCI) Central Institutional Review Board (IRB) and each of the following independent ethics committees: University Health Network Princess Margaret Cancer Center Research Ethics Board, City of Hope Comprehensive Cancer Center IRB, Yale School of Medicine IRB and Human Investigations Committee, Dana- Farber Cancer Institute single IRB, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Clinical Research Review Committee, The Mayo Clinic IRB, Rutgers Cancer Institute of New Jersey IRB, The Ohio State University Office of Responsible Research Practices and IRB, University . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.